Colonoscopy, endoscopy, fecal calprotectin, CRP, imaging, intestinal ultrasound, and monitoring research.
Page 24 of 33 · 1560 articles
MR enterography is an important tool to measure transmural inflammation in ileal Crohn's disease, but many patients find the oral distension agents unpleasant. Demonstrating that non-distended MR enterography yields...
Low zinc levels were linked with higher one-year relapse risk in UC patients in remission; knowing zinc status might add prognostic information beyond standard labs.
Older adults with ulcerative colitis can rarely develop large-vessel giant cell arteritis as an extraintestinal complication.
CDI is a common and important complication in people with IBD; which antibiotic is used can affect recurrence risk and subsequent need for surgery. This review pools available studies and suggests vancomycin may reduce...
Personalizing adalimumab dosing could reduce underexposure, treatment failure, and immunogenicity for people with IBD. Validated popPK models are a key step toward reliable model-informed precision dosing in clinical...
IBD may involve small-vessel changes beyond the gut. If reproducible, retinal microvascular alterations detectable by OCTA could offer a non-invasive window into systemic microvascular involvement in IBD.
The study maps cellular and molecular programs that drive transformation of fissures into fistulas in Crohn's disease, pointing to early remodeling processes and specific molecular pathways that could be targeted to...
The study links symptom trajectories during the first year of biologic treatment to endoscopic remission, suggesting that week 20 symptom assessment may help predict long-term outcomes for people with UC on biologics.
The study suggests a herbal formula (H7F) may protect intestinal barrier function, modulate the gut microbiome, and suppress IL-17/NF-κB inflammation in a mouse colitis model—mechanisms relevant to IBD pathophysiology.
Identifying an RNF213-marked Treg subset may help researchers understand immune mechanisms active in UC and could lead to new biomarker or therapeutic targets in the future.
The review connects molecular cell-cycle changes to the progression from chronic IBD to colorectal cancer, pointing to pathways and cell-cycle regulators that could become prevention or treatment targets for...
Remote text monitoring is appealing as a low-cost way to support people with IBD on biologics, but this trial suggests it may not boost quality of life or adherence over 4 months when adherence is already high. Patients...
Improved methods for profiling mucosa-associated microbiota from routine archival FFPE biopsies could expand research using stored pediatric gut samples, helping identify microbiome features linked to Crohn’s disease and...
Patients and clinicians often face primary non-response to anti‑TNF therapy. Identifying reproducible mucosal gene-expression patterns linked to non-response helps explain biological differences between responders and...
Patients and clinicians using vedolizumab for ulcerative colitis may expect early improvement, but a lack of remission at week 2 does not reliably predict long-term failure. Clear predictive metrics are needed before...
A nationwide clinician survey identifies major variation in how acute severe ulcerative colitis is diagnosed, monitored, and when rescue therapy or surgery is used — differences that can affect patient outcomes and...
Noninvasive stool markers that track endoscopic inflammation could reduce the need for frequent pediatric endoscopies, easing burden and risk for children with IBD. Strong correlation with endoscopy suggests these tests...
This survey shows IUS is increasingly recognized but underutilized in China due to limited training and varied perceptions across specialties; patients generally like IUS but many have safety concerns. Addressing...
This abstract reports that etrasimod improved multiple measures of disease activity versus placebo in patients who had inadequate response to conventional UC therapies, indicating it may be a useful first-line advanced...
A broad comparison of many maintenance therapies helps patients and clinicians understand which drugs have trial evidence for preventing relapse or loss of response in Crohn's disease. The review highlights adalimumab,...
People with IBD (including those on TNF inhibitors) may benefit from research that explains why some patients don’t respond to anti-TNF drugs and that points to new biologic targets. Understanding cell types and...
This review addresses cancer risk tied to IBD treatments, a common and important concern for people on long-term immunosuppression or advanced therapies.
Spatial, high-plex mapping of immune cells in the colon helps reveal how immune cells and stromal cells are organized in IBD versus normal tissue. That information could help researchers identify new biomarkers or...
The abstract suggests a new AhR-targeting drug candidate, EQ504, may more strongly drive epithelial repair and barrier-related gene changes in lab models than an existing clinical AhR agonist, which could be relevant to...
Cure8 could only read part of this source from Intestinal Research, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease and Medications.
A Phase 2/3 trial of guselkumab could expand biologic treatment options for people with moderate to severe ulcerative colitis if efficacy and safety are demonstrated. The trial’s use of standard clinical endpoints...
The trial explores a new way to boost regulatory T cells using low-dose IL-2, which could offer an alternative mechanism for people with Crohn's disease who haven't responded to existing therapies. It also links immune...
The study could improve prediction of who among first-degree relatives will develop Crohn's disease by combining blood biomarkers and lifestyle data, which may help earlier detection or targeted monitoring.
A successful Phase 3 trial could add guselkumab — an IL-23–targeting biologic — as a treatment option for people with moderate to severe Crohn's disease, especially those who haven’t responded to prior therapies.
If confirmed, αvβ6 autoantibodies could help identify people at higher risk for ulcerative colitis and point to a new mechanism (blockade of epithelial TGF‑β activation) that contributes to mucosal inflammation.
If you have ulcerative colitis and cannot tolerate 5-ASA (mesalamine), this study suggests you may be at higher risk of progressing to difficult-to-treat disease, particularly if your intolerance fits an acute...
Patients, families, and clinicians can use registry-based predictors to better understand which children with Crohn’s disease may be at higher risk of slower or absent remission, which could inform monitoring and...
Based on the title and source metadata, this appears to be a regulatory update related to Colorectal cancer, Blood Test, and Tests and monitoring. The original article is from hmpgloballearningnetwork.com.
For people with IBD who do not respond to standard biologic doses, escalating the dose appears common in routine care and was associated with better short-term remission rates and reduced healthcare use in this registry...
RDW is part of a routine complete blood count and, if reliably associated with IBD activity, could offer a low-cost, widely available adjunctive biomarker for detecting disease and monitoring activity.
Children with autoimmune gastrointestinal diseases can have impaired bone health.
If validated, epithelial CXCL1 could become a tissue biomarker that helps track remission specifically in ulcerative colitis and serve as a functional readout for epithelial-directed therapies tested in patient-derived...
Early changes in stool tests (qFIT and fecal calprotectin) might help predict which biologic‑naive ulcerative colitis patients will relapse or need escalation to biologic/JAK therapy. If validated, such markers could...
Early, noninvasive stool tests (fecal calprotectin and FIT) might identify whether vedolizumab or infliximab is likely to work within weeks instead of months. That could let patients and clinicians make treatment...
Cure8 found this source from Alimentary pharmacology & therapeutics, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Tests and monitoring. Open the original article for the...
Noninvasive TUS can help detect small-bowel inflammation and stenosis in Crohn's disease with high specificity, potentially reducing the need for immediate invasive testing. However, its sensitivity varies by small-bowel...
This study could clarify which imaging test—MRE or IUS—is more accurate or appropriate for monitoring treatment response in Crohn's disease, potentially standardising follow-up and informing patient and clinician...
The study indicates that active inflammation—measured by CDAI and PDAI—drives poorer quality of life in Crohn's disease more than the mere presence of fistulas. That shifts focus toward controlling inflammation to...
The review suggests RDW, an inexpensive and widely available blood test parameter, is higher in IBD and correlates with disease activity—meaning it might help clinicians monitor disease alongside other tests.
This meta-analysis pooled long‑term comparative data suggesting vedolizumab may have advantages over infliximab for treatment persistence, 12‑month remission, and safety in biologic‑naive ulcerative colitis — information...
People with IBD and their clinicians often rely on MRI for monitoring disease; knowing that MRI techniques can also detect other bowel problems helps explain imaging choices and what radiologists may be looking for when...
NICE’s patient summary explains care expectations for people with Crohn’s disease, emphasising shared decision-making, symptom control, and understanding treatment options — practical points that affect everyday...
The study identifies a natural compound that reduced inflammation and improved multiple aspects of intestinal barrier function in a zebrafish IBD model, suggesting a new candidate for preclinical drug discovery relevant...
